Figure 7
D-series resolvins RvD1 and aspirin-triggered RvD1 (AT-RvD1) increase extracellular signal–regulated kinase 1/2 (ERK1/2) activity in conjunctival goblet cells. Response of ERK1/2 activity to (a and c) RvD1 (upper panels) or AT-RvD1 (bottom panels) in rat conjunctival goblet cells. Concentration (left panels)- and time (right panels)-dependence of ERK1/2 activity in a representative western blotting experiment. Mean of three experiments using (b) RvD1 (closed bars) and AT-RvD1 (open bars) for 5 min and (d) RvD1 (10−9 M, closed bars) and AT-RvD1 (10−10 M, open bars). *P<0.05 (vehicle vs. resolvin).
